Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Dec 15, 2011

Lonza Expands Small Molecule Manufacturing Facility in China

  • Lonza is expanding its early-phase small-molecule manufacturing facility in Nansha, China, to help meet the demands of customers globally. A new cGMP kilo lab and an additional small-scale train have been added to the site’s existing small-scale trains for clinical material, three large-scale API trains for metric tons, and cGMP laboratories to meet gram-scale requirements.

    Lonza says it has been manufacturing small molecules in China since 1996. “This investment speeds our efforts to establish the Lonza Nansha site as a standard-of-quality to serve our global customer base for all material needs from gram-scale to metric tons,” comments Stefan Stoffel, head of Lonza’s chemical manufacturing business unit. “With this expansion, Lonza’s FDA-approved Nansha site now offers a fully integrated end-to-end development and manufacturing solution for small molecules.”

Related content

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »